BenevolentAI Investor Presentation Deck
Fundamental shift in Al landscape and market
opportunity - BAI is uniquely positioned to lead
At BenevolentAl, we build technology in the service of science
Market Evolution
Fundamental shift in AI
landscape will result in a
wide adoption of Al tools
across biopharma R&D
Companies now demand
products that are
tech-centric, modular,
bio-specific, and secure
Go-Forward Strategy
5+ years of experience building highly specific, biopharma sector and
domain specialised LLMs and Al models for use across R&D
Leverages our core competencies in drug discovery and data
integration to support development of new products that scientists need
Capitalising on our technology to scale thousands of scientists
across biopharma globally
Focus on solving for day-to-day scientific needs across biopharma R&D
Platform built on a successful track record of impact and domain/sector
specific AI LLM/NLP expertise
Benevolent
6View entire presentation